162 related articles for article (PubMed ID: 30586495)
1. Cost variation and savings opportunities in the Oncology Care Model.
Baumgardner J; Shahabi A; Zacker C; Lakdawalla D
Am J Manag Care; 2018 Dec; 24(12):618-623. PubMed ID: 30586495
[TBL] [Abstract][Full Text] [Related]
2. Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.
Baumgardner J; Shahabi A; Linthicum M; Vine S; Zacker C; Lakdawalla D
J Manag Care Spec Pharm; 2018 Jun; 24(6):504-513. PubMed ID: 29799330
[TBL] [Abstract][Full Text] [Related]
3. Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model.
Baumgardner JR; Shahabi A; Linthicum MT; Zacker C; Lakdawalla DN
J Oncol Pract; 2018 Nov; 14(11):e699-e710. PubMed ID: 30423271
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
Walker B; Frytak J; Hayes J; Neubauer M; Robert N; Wilfong L
JAMA Netw Open; 2020 May; 3(5):e205165. PubMed ID: 32421185
[TBL] [Abstract][Full Text] [Related]
5. Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Halilova KI; Sullivan MM; Rocconi RP; Azuero A; Kvale EA; Huh WK; Partridge EE; Pisu M
J Oncol Pract; 2018 Jun; 14(6):e375-e383. PubMed ID: 28981388
[TBL] [Abstract][Full Text] [Related]
6. Area-level variations in cancer care and outcomes.
Keating NL; Landrum MB; Lamont EB; Bozeman SR; McNeil BJ
Med Care; 2012 May; 50(5):366-73. PubMed ID: 22437623
[TBL] [Abstract][Full Text] [Related]
7. What drives variation in spending for breast cancer patients within geographic regions?
Sinaiko AD; Chien AT; Hassett MJ; Kakani P; Rodin D; Meyers DJ; Fraile B; Rosenthal MB; Landrum MB
Health Serv Res; 2019 Feb; 54(1):97-105. PubMed ID: 30318592
[TBL] [Abstract][Full Text] [Related]
8. Regional variation in spending and survival for older adults with advanced cancer.
Brooks GA; Li L; Sharma DB; Weeks JC; Hassett MJ; Yabroff KR; Schrag D
J Natl Cancer Inst; 2013 May; 105(9):634-42. PubMed ID: 23482657
[TBL] [Abstract][Full Text] [Related]
9. Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
Bekelman JE; Gupta A; Fishman E; Debono D; Fisch MJ; Liu Y; Sylwestrzak G; Barron J; Navathe AS
J Clin Oncol; 2020 Dec; 38(34):4055-4063. PubMed ID: 33021865
[TBL] [Abstract][Full Text] [Related]
10. High-Cost Patients and Preventable Spending: A Population-Based Study.
de Oliveira C; Cheng J; Chan K; Earle CC; Krahn M; Mittmann N
J Natl Compr Canc Netw; 2020 Jan; 18(1):23-31. PubMed ID: 31910386
[TBL] [Abstract][Full Text] [Related]
11. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer.
Xu X; Herrin J; Soulos PR; Saraf A; Roberts KB; Killelea BK; Wang SY; Long JB; Wang R; Ma X; Gross CP
Health Serv Res; 2016 Feb; 51(1):167-86. PubMed ID: 26119176
[TBL] [Abstract][Full Text] [Related]
12. Contribution of preventable acute care spending to total spending for high-cost Medicare patients.
Joynt KE; Gawande AA; Orav EJ; Jha AK
JAMA; 2013 Jun; 309(24):2572-8. PubMed ID: 23797716
[TBL] [Abstract][Full Text] [Related]
13. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
14. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
15. Opportunities for Savings in Risk Arrangements for Oncologic Care.
Landon BE; Lam MB; Landrum MB; McWilliams JM; Meneades L; Wright AA; Keating NL
JAMA Health Forum; 2023 Sep; 4(9):e233124. PubMed ID: 37713209
[TBL] [Abstract][Full Text] [Related]
16. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
Kreys ED; Koeller JM
J Oncol Pract; 2013 Sep; 9(5):e241-7. PubMed ID: 23943896
[TBL] [Abstract][Full Text] [Related]
17. Variation in Physician Spending and Association With Patient Outcomes.
Tsugawa Y; Jha AK; Newhouse JP; Zaslavsky AM; Jena AB
JAMA Intern Med; 2017 May; 177(5):675-682. PubMed ID: 28288254
[TBL] [Abstract][Full Text] [Related]
18. Dartmouth Atlas Area-Level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients?
Keating NL; Landrum MB; Huskamp HA; Kouri EM; Prigerson HG; Schrag D; Maciejewski PK; Hornbrook MC; Haggstrom DA
Health Serv Res; 2016 Aug; 51(4):1584-94. PubMed ID: 26799913
[TBL] [Abstract][Full Text] [Related]
19. Considerations in the Care of Non-Small-Cell Lung Cancer: The Value Imperative.
Kelly R; Houseknecht S
Oncology (Williston Park); 2018 Nov; 32(11):534-40. PubMed ID: 30474101
[TBL] [Abstract][Full Text] [Related]
20. Modeling Episode-Based Payments for Cancer Using Commercial Claims Data.
Polson M; Lord T; Evangelatos T; Kangethe A; Speicher LC; Barrientos S; Zacker C
J Manag Care Spec Pharm; 2019 Feb; 25(2):235-245. PubMed ID: 30698092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
